EXICURE

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

#SimilarOrganizations #People #Financial #Website #More

EXICURE

Social Links:

Industry:

Biotechnology Genetics Life Science Therapeutics

Founded:

2009-01-01

Address:

Chicago, Illinois, United States

Country:

United States

Website Url:

http://www.exicuretx.com

Total Employee:

11+

Status:

Active

Contact:

Total Funding:

105.45 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome

Similar Organizations

cerevance-logo

Cerevance

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

scholar-rock-logo

Scholar Rock

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Current Advisors List

david-r-walt_image

David R. Walt Board Of Director @ Exicure
Board_member

not_available_image

C. Shad Thaxton Board Of Director @ Exicure
Board_member

helen-s-kim_image

Helen S. Kim Board Of Director @ Exicure
Board_member

not_available_image

Jay R. Venkatesan Board Of Director @ Exicure
Board_member

jeffrey-cleland_image

Jeffrey Cleland Board Member @ Exicure
Board_member
2019-07-01

Current Employees Featured

david-a-giljohann_image

David A. Giljohann
David A. Giljohann CEO @ Exicure
CEO
2013-09-01

sergei-gryaznov_image

Sergei Gryaznov
Sergei Gryaznov CTO @ Exicure
CTO

chad-a-mirkin_image

Chad A. Mirkin
Chad A. Mirkin CEO @ Exicure
CEO

not_available_image

C. Shad Thaxton
C. Shad Thaxton Founder @ Exicure
Founder

weston-daniel_image

Weston Daniel
Weston Daniel Vice President of Translational Research @ Exicure
Vice President of Translational Research
2020-01-01

Founder

not_available_image

C. Shad Thaxton

Stock Details

Company's stock symbol is NASDAQ:XCUR

Investors List

luye-pharma_image

Luye Pharma

Luye Pharma investment in Venture Round - Exicure

ht-capital-5afe_image

HT Capital

HT Capital investment in Venture Round - Exicure

alumni-ventures-group_image

Alumni Ventures

Alumni Ventures investment in Venture Round - Exicure

knoll-capital-management_image

Knoll Capital Management

Knoll Capital Management investment in Venture Round - Exicure

abbvie-biotech-ventures_image

AbbVie Biotech Ventures

AbbVie Biotech Ventures investment in Venture Round - Exicure

katalyst-securities_image

Katalyst Securities

Katalyst Securities investment in Venture Round - Exicure

david-r-walt_image

David R. Walt

David R. Walt investment in Venture Round - Exicure

tempus-3_image

Tempus

Tempus investment in Venture Round - Exicure

craig-mundie_image

Craig Mundie

Craig Mundie investment in Venture Round - Exicure

mark-tomkins_image

Mark Tompkins

Mark Tompkins investment in Venture Round - Exicure

Official Site Inspections

http://www.exicuretx.com Semrush global rank: 4.31 M Semrush visits lastest month: 2.66 K

Host Informations
Whois Informations

Loading ...

More informations about "Exicure" on Search Engine